The rightsizing at BioMarin continues to take its toll as CEO Alexander Hardy devises a new corporate strategy for the rare disease biotech.
BioMarin plans to cut about 225 employees, or about 7% of its global workforce, the California biotech said in a securities filing (PDF) Wednesday.
